Gilead Sciences to Buy Ouro Medicines for $2.2 Billion and Expand Autoimmune Drug Pipeline

Gilead Sciences to Buy Ouro Medicines for $2.2 Billion

Gilead Sciences is a biopharmaceutical company in California. It is involved in the research and development of antiviral drugs. They manufacture drugs for the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead Sciences Acquires Ouro Medicines for $2.2 Billion. This big move shows that the biotech industry is growing rapidly.

This acquisition news has got a lot of attention. This focuses on designing better autoimmune drugs for patients worldwide. This is very important because many people are living with autoimmune diseases. Under these conditions, the own immune system mistakenly attacks the healthy cells in the body. 

Diseases like autoimmune hemolytic anemia and immune thrombocytopenia can make people’s everyday lives worse. So this investment in better treatment would bring real hope to patients.

The agreement entails an upfront payment of $1.675 billion from Gilead Sciences, along with an additional $500 million based on future milestones. Ouro Medicines may receive additional funding if their new treatments succeed.

OM336, also known as gamgertamig, is the most important part of this deal. This drug is designed to target specific immune cells (B cells) and remove them quickly after a simple injection under the skin. It has already shown positive results in patients with severe autoimmune diseases in the early Phase 1/2 trials 

OM336 has received Fast Track and Orphan Drug Designation. These important recognitions help speed up the development of treatments for serious and rare conditions such as immune thrombocytopenia. This means patients gain access to these autoimmune drugs more quickly. 

Gilead Sciences is not working alone on this. The company plans to partner with Galapagos NV. This helps in developing the Ouro Medicines Portfolio. Galapagos will share 50% of the upfront and milestone costs under this partnership. It will also take over most of Ouro’s operations and continue developing the drugs until they reach late-stage trials. 

Both companies will share development costs equally. However, Gilead Sciences will keep full rights to sell the drugs worldwide, except in Greater China. Because in Greater China, Keymed Biosciences already has the rights. In return, Gilead will pay Galapagos a royalty of 20% to 23% on sales.

This is the second big deal for Gilead Sciences in just one month. The company also announced to acquire Arcellx for around $7.8 billion in February 2026. This deal focuses more on cancer treatments, especially immunotherapies. 

Gilead Sciences Acquires Ouro Medicines to make a strong investment in the future of medicine. The company is trying to solve the biggest health problems, such as cancer and autoimmune diseases. 

For students and young professionals, this is a great example of how science, business, and innovation come together. Behind every big deal like this, there is one main goal: helping patients live better, healthier lives.